Wednesday, November 18, 2026
The top medical stories of the day, as they ran.
Morning edition
15 stories
- 1U.S. loses measles elimination status after 12 months of transmissionInfectious disease · 17 outlets
- 2White House withdraws Heidi Overton’s nomination to lead the FDADrugs and FDA · 9 outlets
- 3FDA approves Roche’s giredestrant combination for ESR1-mutated breast cancerDrugs and FDA · 4 outlets
- 4HHS finalizes HIPAA rule to speed patients’ access to health recordsHealth policy · 4 outlets
- 5AR1001 slowed Alzheimer’s decline in one trial group but not overallResearch · 3 outlets
- 6Marrow raises $173 million to develop blood disorder drugsIndustry · 4 outlets
- 7FDA approves neladalkib for previously treated ALK-positive lung cancerDrugs and FDA · 3 outlets
- 8FDA approves Gazyva for adults with primary membranous nephropathyDrugs and FDA · 2 outlets
- 9Experts warn H5N1 cases may be missed in Washington outbreakInfectious disease · 1 outlet
- 10Cognito reports Alzheimer’s trial results and plans FDA approval bidMedical devices · 2 outlets
- 11Larbi recalls three Yellow Dock Root lots over possible Salmonella contaminationRecalls · 1 outlet
- 12John H. Powers III appointed director of NIH infectious disease instituteInfectious disease · 2 outlets
- 13ECDC urges action as antibiotic resistance spreadsPublic health · 2 outlets
- 14Study links beer and spirits with acute kidney injury, but not wineResearch · 2 outlets
- 15Teladoc offers employers an option to contribute to GLP-1 costsInsurance · 2 outlets
Evening edition
17 stories
- 1U.S. loses measles elimination status after year of continuous transmissionInfectious disease · 18 outlets
- 2White House withdraws Heidi Overton’s nomination to lead the FDADrugs and FDA · 13 outlets
- 3FDA approves adrabetadex for infantile-onset Niemann-Pick diseaseDrugs and FDA · 4 outlets
- 4FDA approves neladalkib for previously treated ALK-positive lung cancerDrugs and FDA · 3 outlets
- 5HHS finalizes HIPAA rule to speed patients’ access to health recordsHealth policy · 3 outlets
- 6Hospitals rush to patch Java flaw after CISA alertHospitals · 2 outlets
- 7FDA approves Roche’s giredestrant combination for ESR1-mutated breast cancerDrugs and FDA · 2 outlets
- 8FDA cites modest benefit and safety risks in rejecting Summit’s lung cancer drugDrugs and FDA · 3 outlets
- 9Hims & Hers launches five compounded peptide and longevity treatmentsDrugs and FDA · 3 outlets
- 10Diranersen showed continued benefit in Alzheimer’s trial extension at 2 yearsResearch · 2 outlets
- 11CMS proposes rule to combat fraud across federal health programsHealth policy · 2 outlets
- 12Marrow raises $173 million to develop blood disorder drugsIndustry · 3 outlets
- 13Sanders plans to push Medicare for All in next CongressMedicare and Medicaid · 2 outlets
- 14AR1001 slowed Alzheimer’s decline in one trial group but not overallResearch · 2 outlets
- 15Teladoc offers employers an option to contribute to GLP-1 costsInsurance · 2 outlets
- 16Study finds AI-generated discharge summaries rated above clinician-written versionsResearch · 2 outlets
- 17GMC mistakenly sent complaint details about 223 doctors to newspaperHealth policy · 2 outlets